Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03810703
Other study ID # IRB16-1293
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 9, 2017
Est. completion date August 9, 2018

Study information

Verified date May 2022
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Young adults who exhibit "bipolar phenotype" (BPP), defined as occasional episodes of mood elevation and heightened activity, are at risk for several psychiatric disorders, including problem use of drugs and alcohol. Mood elevation has been linked to higher alcohol consumption and alcohol use disorders. Individuals with BPP show elevated lifetime prevalence of alcohol use disorders (between 39%-61%), figures that exceed those reported in both major depression and schizophrenia. Recently, the investigators demonstrated in a controlled laboratory study that individuals with BPP (but not meeting criteria for full Bipolar I Disorder), report dampened responses to a single dose of alcohol, compared to placebo. In the current study, the investigators seek to extend these findings to determine if young adults reporting BPP, based on a questionnaire, will exhibit reduced responses to other rewarding stimuli, such as d-amphetamine and sweet tastes. The investigators hypothesize that the BPP individuals will exhibit dampened subjective responses to stimulant and sweet taste rewards compared to healthy controls.


Description:

This study will extend the understanding of risk factors for drug or alcohol misuse, or other reward-related behaviors. The investigators previously showed that individuals who report occasional feelings of high energy and excitability experience less effect from a single dose of alcohol, compared to people who have not experienced these effects. Now the investigators wish to determine if this dampened response also occurs with other rewards, namely feelings of wellbeing after a dose of amphetamine, or liking of a sweet solution. Individuals who exhibit the BPP (i.e., periods of excitability) also are more likely to develop alcohol problems, substance misuse, and weight gain and obesity. Therefore, the investigators will test the working hypothesis that young adults who report having these experiences, based on a questionnaire measure (i.e., BPP individuals) will show dampened subjective responses to both single oral doses of amphetamine or sweet palatable tastes. The investigators will also obtain objective measures (e.g. Respiratory Sinus Arrhythmia and heart rate) to amphetamine and sweet taste, to establish whether the dampened subjective response extends to physiological indices as well. This study will extend the previous literature regarding the blunted effects of alcohol in BPP individuals and will suggest possible mechanisms that promote broader addictive behaviors in individuals with mood disturbance. Importantly, the investigators are proposing to test individuals at a relatively young age, 18-19 years. This is important to identify a risk factor, that is thought to pre-date use of drugs. In older participants, it would be difficult to separate the role of the pre-existing trait from the effect of habitual drug or alcohol use that escalates markedly after age 20.


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date August 9, 2018
Est. primary completion date August 9, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 19 Years
Eligibility Inclusion Criteria: - Aged 18-19 years old - BMI of 19-26 - Physical/EKG/Medical History/Medications Approved by Physician for d-amphetamine - at least High School education - Fluent in English Exclusion Criteria: - No Current Mood, Anxiety, Eating or Psychotic Disorder - No current psychotropic medication - No Recent Drug Dependence - < 4 alcoholic drinks/day for males; < 3 alcoholic drinks/day for females (monthly average) - No weekly (or more frequent) illicit drug use - No women who are pregnant, nursing, or planning pregnancy within 3 months (birth control is okay)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo oral capsule
Placebo oral capsule
d-amphetamine 10 mg oral capsule
d-amphetamine 10 mg oral capsule
d-amphetamine 20 mg oral capsule
d-amphetamine 20 mg oral capsule

Locations

Country Name City State
United States University of Chicago Chicago Illinois
United States University of Chicago Medical Center - Human Behavioral Pharmacology Lab Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

References & Publications (21)

Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, Lewis L, McElroy SL, McNulty JP, Wagner KD. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry. 2003 Apr;64(4):425-32. doi: 10.4088/jcp.v64n0412. — View Citation

Chandler RA, Wang PW, Ketter TA, Goodwin GM. A new US-UK diagnostic project: mood elevation and depression in first-year undergraduates at Oxford and Stanford universities. Acta Psychiatr Scand. 2008 Jul;118(1):81-5. doi: 10.1111/j.1600-0447.2008.01193.x. — View Citation

de Lauzon B, Romon M, Deschamps V, Lafay L, Borys JM, Karlsson J, Ducimetiere P, Charles MA; Fleurbaix Laventie Ville Sante Study Group. The Three-Factor Eating Questionnaire-R18 is able to distinguish among different eating patterns in a general population. J Nutr. 2004 Sep;134(9):2372-80. doi: 10.1093/jn/134.9.2372. — View Citation

Francis LJ, Robbins M, Louden SH, Haley JM. A revised psychoticism scale for the revised Eysenck personality questionnaire: a study among clergy. Psychol Rep. 2001 Jun;88(3 Pt 2):1131-4. doi: 10.2466/pr0.2001.88.3c.1131. — View Citation

Gontkovsky ST. Sensitivity of the Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II) to the neurocognitive deficits associated with the semantic dementia variant of frontotemporal lobar degeneration: A case study. Appl Neuropsychol Adult. 2017 May-Jun;24(3):288-293. doi: 10.1080/23279095.2016.1154857. Epub 2016 Apr 21. — View Citation

Grossman P, Taylor EW. Toward understanding respiratory sinus arrhythmia: relations to cardiac vagal tone, evolution and biobehavioral functions. Biol Psychol. 2007 Feb;74(2):263-85. doi: 10.1016/j.biopsycho.2005.11.014. Epub 2006 Nov 1. — View Citation

Grossman P, van Beek J, Wientjes C. A comparison of three quantification methods for estimation of respiratory sinus arrhythmia. Psychophysiology. 1990 Nov;27(6):702-14. doi: 10.1111/j.1469-8986.1990.tb03198.x. — View Citation

Haertzen CA. Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep. 1966 Feb;18(1):163-94. doi: 10.2466/pr0.1966.18.1.163. No abstract available. — View Citation

Hirschfeld RM, Holzer C, Calabrese JR, Weissman M, Reed M, Davies M, Frye MA, Keck P, McElroy S, Lewis L, Tierce J, Wagner KD, Hazard E. Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry. 2003 Jan;160(1):178-80. doi: 10.1176/appi.ajp.160.1.178. — View Citation

Hoeppner BB, Stout RL, Jackson KM, Barnett NP. How good is fine-grained Timeline Follow-back data? Comparing 30-day TLFB and repeated 7-day TLFB alcohol consumption reports on the person and daily level. Addict Behav. 2010 Dec;35(12):1138-43. doi: 10.1016/j.addbeh.2010.08.013. Epub 2010 Aug 13. — View Citation

Jacob T, Seilhamer RA, Bargeil K, Howell DN. Reliability of Lifetime Drinking History among alcohol dependent men. Psychol Addict Behav. 2006 Sep;20(3):333-7. doi: 10.1037/0893-164X.20.3.333. — View Citation

Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: d-amphetamine. Psychopharmacology (Berl). 1980;71(3):275-9. doi: 10.1007/BF00433062. — View Citation

Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997 Apr;54(4):313-21. doi: 10.1001/archpsyc.1997.01830160031005. — View Citation

Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511-8. — View Citation

Rock PL, Goodwin GM, Harmer CJ. The common adolescent bipolar phenotype shows positive biases in emotional processing. Bipolar Disord. 2010 Sep;12(6):606-15. doi: 10.1111/j.1399-5618.2010.00859.x. — View Citation

Trost S, Diekhof EK, Mohr H, Vieker H, Kramer B, Wolf C, Keil M, Dechent P, Binder EB, Gruber O. Investigating the Impact of a Genome-Wide Supported Bipolar Risk Variant of MAD1L1 on the Human Reward System. Neuropsychopharmacology. 2016 Oct;41(11):2679-87. doi: 10.1038/npp.2016.70. Epub 2016 May 13. — View Citation

Waleeprakhon P, Ittasakul P, Lotrakul M, Wisajun P, Jullagate S, Ketter TA. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire Thai version. Neuropsychiatr Dis Treat. 2014 Aug 18;10:1497-502. doi: 10.2147/NDT.S67842. eCollection 2014. — View Citation

Weafer J, Burkhardt A, de Wit H. Sweet taste liking is associated with impulsive behaviors in humans. Front Behav Neurosci. 2014 Jun 17;8:228. doi: 10.3389/fnbeh.2014.00228. eCollection 2014. — View Citation

White TL, Justice AJ, de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002 Nov;73(4):729-41. doi: 10.1016/s0091-3057(02)00818-3. — View Citation

Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, Howes MJ, Kane J, Pope HG Jr, Rounsaville B, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry. 1992 Aug;49(8):630-6. doi: 10.1001/archpsyc.1992.01820080038006. — View Citation

Yip SW, Doherty J, Wakeley J, Saunders K, Tzagarakis C, de Wit H, Goodwin GM, Rogers RD. Reduced subjective response to acute ethanol administration among young men with a broad bipolar phenotype. Neuropsychopharmacology. 2012 Jul;37(8):1808-15. doi: 10.1038/npp.2012.45. Epub 2012 Apr 11. — View Citation

* Note: There are 21 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome. End of study (Baseline - time 0 and approximately 4 weeks later)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT06184581 - Lithium Versus Lamotrigine in Bipolar Disorder, Type II Phase 4
Active, not recruiting NCT03484494 - Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression N/A
Recruiting NCT05400785 - Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning N/A
Completed NCT05340504 - Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder Phase 2
Active, not recruiting NCT05249309 - Naturalistic Study of Ketamine in the Treatment of Depression
Recruiting NCT04211428 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
Completed NCT03822416 - Treating Smokers With Mental Illness Phase 2
Completed NCT01588457 - Sequential Multiple Assignment Treatment for Bipolar Disorder Phase 4
Completed NCT03156504 - The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Phase 4
Recruiting NCT05004896 - Ketamine for Treatment-Resistant Bipolar Disorder Phase 2
Terminated NCT02491307 - Ginger.io Behavioral Health Study N/A
Recruiting NCT05427123 - Children's Bipolar Network Treatment Trial I
Not yet recruiting NCT05705063 - Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness N/A
Recruiting NCT05065294 - Psilocybin Therapy for Depression in Bipolar II Disorder Phase 2